A New Force in Alternate Site?
When Bergen Brunswig bought rival drug wholesaler Durr-Fillauer in an effort to shore up its coverage in the Southeast, it also got one of the country’s most respected alternate site medical/surgical supply dealers. Many in the industry expected Bergen to sell off Durr’s med/surg piece. But Bergen never did divest it, and with its recent acquisition of Colonial appears to be venturing even further into med/surg.
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.